Sep 30, 2024 8:00 am EDT Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Sep 5, 2024 8:43 pm EDT UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Sep 5, 2024 8:00 am EDT Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Aug 20, 2024 8:00 am EDT Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
Aug 13, 2024 8:00 am EDT Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
Jul 10, 2024 8:00 am EDT Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
Jun 13, 2024 8:00 am EDT Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
Jun 6, 2024 7:57 am EDT Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
May 10, 2024 8:00 am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update